SCHEMBL289360

SCHEMBL289360

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
CYP19A1 P11511 4/20 0.54
PPARG P37231 3/20 0.54
OXER1 Q8TDS5 3/20 0.54
MAPT P10636 3/20 0.54
RXRA P19793 2/20 0.54
FFAR1 O14842 2/20 0.54
CNR1 P21554 2/20 0.52
PTGS1 P23219 4/20 0.50
F7 P08709 3/20 0.50
F3 P13726 3/20 0.50
PPARA Q07869 3/20 0.50
KMT2A Q03164 2/20 0.50
PPARD Q03181 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
NR1I2 O75469 2/20 0.47
PTGS2 P35354 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18339353 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL88350 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL1245698 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL19920999 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL21052414 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL88349 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL1245776 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL19921001 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL9155208 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT
SCHEMBL290480 1.00 ALDH1A1 (0.54) ALDH1A1CYP19A1PPARGOXER1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107406375-B Process for producing unsaturated ketone compound 埃维克辛公司 2020-09-15 CN claimed
EP-3247700-B1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2019-03-20 EP claimed
US-10183911-B2 Process for the preparation of a polyunsaturated ketone compound AVEXXIN AS (NO) 2019-01-22 US claimed
US-20180009745-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2018-01-11 US claimed
EP-3247700-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND Avexxin AS (NO) 2017-11-29 EP claimed
WO-2016116634-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2016-07-28 WO claimed
CN-107406375-B Process for producing unsaturated ketone compound 埃维克辛公司 2020-09-15 CN disclosed
US-20190322620-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2019-10-24 US disclosed
US-20190322620-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2019-10-24 US disclosed
EP-2427415-B1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS BASF AS (NO) 2019-03-20 EP disclosed
EP-3247700-B1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2019-03-20 EP disclosed
EP-3247700-B1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND AVEXXIN AS (NO) 2019-03-20 EP disclosed
US-10183911-B2 Process for the preparation of a polyunsaturated ketone compound AVEXXIN AS (NO) 2019-01-22 US disclosed
WO-2010128401-A9 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2011-12-08 WO disclosed
US-20110105781-A1 Process for the Synthesis of Long-Chain Fatty Acids MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2011-05-05 US disclosed
WO-2010128401-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2010-11-11 WO disclosed
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PRONOVA BIOPHARMA NORGE AS (NO) 2010-02-11 US disclosed
EP-2147910-A1 Novel lipid compounds Pronova BioPharma Norge AS (NO) 2010-01-27 EP disclosed
EP-2094640-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). Pronova BioPharma Norge AS (NO) 2009-09-02 EP disclosed
WO-2008053331-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). PRONOVA BIOPHARMA NORGE A/S (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PPARG, PPARA, FFAR3 ALDH1A1 1088/4885CYP19A1 922/4885PPARG 1/4885
US-20110105781-A1 Process for the Synthesis of Long-Chain Fatty Acids FASN, ELOVL1, ACSL1 ALDH1A1 168/4885CYP19A1 192/4885PPARG 262/4885
US-20180009745-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND GK, GPX4, GLRX3 ALDH1A1 515/4885CYP19A1 1393/4885PPARG 133/4885
US-20190322620-A1 PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND GK, GPX4, SGMS2 ALDH1A1 458/4885CYP19A1 1380/4885PPARG 145/4885
US-10183911-B2 Process for the preparation of a polyunsaturated ketone compound GK, GPX4, GLRX3 ALDH1A1 515/4885CYP19A1 1393/4885PPARG 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.